Molecular genetics

Primordial Genetics Grants Arcturus Therapeutics Exclusive License of an RNA Polymerase for Human and Animal Therapeutics

Retrieved on: 
Wednesday, June 2, 2021
Nucleic acids, Branches of biology, RNA, Gene expression, Molecular biology, Molecular genetics, Arcturus Therapeutics, Messenger RNA

SAN DIEGO, June 2, 2021 /PRNewswire/ -- Primordial Genetics ("Primordial"), a synthetic biology company developing enzymatic production systems for nucleic acids, today announced granting Arcturus Therapeutics Holdings Inc.("Arcturus", Nasdaq: ARCT), a clinical-stage messenger RNA (mRNA) medicines company, an exclusive license of an enzyme for an RNA polymerase (RNApol).

Key Points: 
  • SAN DIEGO, June 2, 2021 /PRNewswire/ -- Primordial Genetics ("Primordial"), a synthetic biology company developing enzymatic production systems for nucleic acids, today announced granting Arcturus Therapeutics Holdings Inc.("Arcturus", Nasdaq: ARCT), a clinical-stage messenger RNA (mRNA) medicines company, an exclusive license of an enzyme for an RNA polymerase (RNApol).
  • Primordial owns proprietary technology relating to RNA manufacturing, specifically its collection of RNA polymerase genes, promoters, and proteins that may be used to synthesize RNA.
  • Primordial is focused on developing improved RNApols for higher efficiency and lower cost manufacturing of mRNAs used in therapeutics and vaccines.
  • "We look forward to the meaningful achievements Arcturus can make with this licensed Primordial Genetics RNA polymerase, from clinical trials to a marketable RNA product that can be used in pharmaceuticals to improve or save lives," said Helge Zieler, PhD, founder and President of Primordial Genetics.

 Arrowhead Pharmaceuticals to Participate in Upcoming Conferences

Retrieved on: 
Wednesday, June 2, 2021
Cardiology, Biotechnology, FDA, Health, General Health, Public relations, Investor relations, Pharmaceutical, Oncology, Communications, Infectious diseases, Genetics, Nucleic acids, Branches of biology, RNA, Biology, Gene expression, Molecular biology, Biotechnology, Molecular genetics, RNA interference, Arrowhead Pharmaceuticals, Forward-looking statement, Small interfering RNA

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them.

Key Points: 
  • Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them.
  • Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes.
  • Any statements contained in this release except for historical information may be deemed to be forward-looking statements.
  • We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

Researchers prepare to send fungi for a ride around the moon

Retrieved on: 
Friday, May 28, 2021
Branches of biology, Biology, Life sciences, Senescence, Cellular processes, Molecular genetics, Mutation, Radiobiology, Melanin, DNA repair, DNA, Radiation therapy

Naval Research Laboratory are preparing experimental samples of fungi to send for a ride around the moon tentatively scheduled for later in 2021 or early 2022.

Key Points: 
  • Naval Research Laboratory are preparing experimental samples of fungi to send for a ride around the moon tentatively scheduled for later in 2021 or early 2022.
  • Fungi have natural mechanisms to protect from and repair DNA damage caused by radiation.
  • Those mechanisms enable the fungi to withstand several hundred times more radiation than humans.
  • This experiment will study the melanin in fungi (which may assist in protecting them from damage), as well as DNA repair pathways (which repair damage once it occurs).

Gene Therapies, Cell Therapies, and COVID-19 Vaccines Viral Vector Contract Manufacturing Outlook Report 2021: Spotlight on AstraZeneca's COVID-19 Vaccine, Luxturna, Zolgensma, Emergent, Catalent - ResearchAndMarkets.com

Retrieved on: 
Thursday, May 27, 2021
Health, Pharmaceutical, Branches of biology, Biology, Life sciences, Gene delivery, Biotechnology, Molecular biology, Virotherapy, Molecular genetics, Viral vector, Vaccine, COVID-19 vaccine, Gene therapy

The "Outlook for Viral Vector Contract Manufacturing - Gene Therapies, Cell Therapies, and COVID-19 Vaccines" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Outlook for Viral Vector Contract Manufacturing - Gene Therapies, Cell Therapies, and COVID-19 Vaccines" report has been added to ResearchAndMarkets.com's offering.
  • This report examines the approvals and manufacturing outlook for three drug molecule types that all require viral vectors in their production: gene therapies, gene-modified cell therapies, and recombinant vector vaccines.
  • The report is critical for benchmarking the CMO industry's capacity to manufacture these vital vaccines and drugs and forecasting future approvals.
  • Analysis of pipeline and marketed gene therapies, cell therapies, and recombinant vector vaccines, by geography, development stage, and clinical trials
    A detailed model forecasting future gene therapy, cell therapy, and recombinant vector vaccine approvals, and associated manufacturing volumes

Synthetic Biology Market worth $30.7 billion by 2026 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Monday, May 24, 2021
Articles, Branches of biology, Biology, Emerging technologies, Biotechnology, Nucleic acids, Synthetic biology, Molecular genetics, Oligonucleotide, Synthetic Genomics, DNA, Organism

However, biosafety, biosecurity, and ethical concerns related to synthetic biology would hamper the growth of this market.

Key Points: 
  • However, biosafety, biosecurity, and ethical concerns related to synthetic biology would hamper the growth of this market.
  • The oligonucleotides and synthetic DNA segment accounted for the largest share of the tool segment in the synthetic biology market in 2020.
  • On the basis of tool, the market is broadly segmented into oligonucleotides & synthetic DNA, enzymes, cloning technology kits, synthetic cells, chassis organisms, and xeno-nucleic acids.
  • In 2020, medical applications segment accounted for the largest share of synthetic biology market.

Synthetic Biology Market worth $30.7 billion by 2026 - Exclusive Report by MarketsandMarkets™

Retrieved on: 
Monday, May 24, 2021
Articles, Branches of biology, Biology, Emerging technologies, Biotechnology, Nucleic acids, Synthetic biology, Molecular genetics, Oligonucleotide, Synthetic Genomics, DNA, Organism

However, biosafety, biosecurity, and ethical concerns related to synthetic biology would hamper the growth of this market.

Key Points: 
  • However, biosafety, biosecurity, and ethical concerns related to synthetic biology would hamper the growth of this market.
  • The oligonucleotides and synthetic DNA segment accounted for the largest share of the tool segment in the synthetic biology market in 2020.
  • On the basis of tool, the market is broadly segmented into oligonucleotides & synthetic DNA, enzymes, cloning technology kits, synthetic cells, chassis organisms, and xeno-nucleic acids.
  • In 2020, medical applications segment accounted for the largest share of synthetic biology market.

Growth Opportunities in Targeted Cancer Therapy & Cancer Diagnostics, Viral Vectors, Multiple Diseases, Retinal Diseases, and Cosmeceuticals, 2021 Market Innovations Report - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 19, 2021
Health, General Health, Branches of biology, Articles, Biology, Biotechnology, Emerging technologies, Molecular genetics, Molecular biology, Gene delivery, Nanomedicine, Personalized medicine, Synthetic biology, Genetic engineering

b'The "Growth Opportunities in Targeted Cancer Therapy & Cancer Diagnostics, Viral Vectors, Multiple Diseases, Retinal Diseases, and Cosmeceuticals" report has been added to ResearchAndMarkets.com\'s offering.\nThis edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) discusses developments in cancer diagnostics and targeted cancer therapy, therapeutics for MDR bacteria, viral vectors, and antibody therapeutics for multiple diseases.\nFurther, innovations in emerging technologies such as synthetic blood and 3D printed implants have also been covered.

Key Points: 
  • b'The "Growth Opportunities in Targeted Cancer Therapy & Cancer Diagnostics, Viral Vectors, Multiple Diseases, Retinal Diseases, and Cosmeceuticals" report has been added to ResearchAndMarkets.com\'s offering.\nThis edition of the Life Science, Health & Wellness Technology Opportunity Engine (TOE) discusses developments in cancer diagnostics and targeted cancer therapy, therapeutics for MDR bacteria, viral vectors, and antibody therapeutics for multiple diseases.\nFurther, innovations in emerging technologies such as synthetic blood and 3D printed implants have also been covered.
  • Use of artificial intelligence/machine learning in drug discovery, viral vector design, and immune profiling are also discussed.
  • Few innovations cover developments in cosmeceuticals for skin and hair care and protein-based sweeteners.\nThe Life Science, Health & Wellness TOE will feature disruptive technology advances in the global life sciences industry.
  • The technologies and innovations profiled will encompass developments across genetic engineering, drug discovery and development, biomarkers, tissue engineering, synthetic biology, microbiome, disease management, as well as health and wellness among several other platforms.\nThe Health & Wellness cluster tracks developments in a myriad of areas including genetic engineering, regenerative medicine, drug discovery and development, nanomedicine, nutrition, cosmetic procedures, pain and disease management and therapies, drug delivery, personalized medicine, and smart healthcare.\n'

Oligonucleotide Synthesis Markets, 2026 by Product (Drug, Synthesized Oligos (Primer, Probe), Reagents), Type (Custom, Predesign), Application (Therapeutic (ASO, siRNA), Research (PCR), Diagnostic) - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 19, 2021
Health, Genetics, Branches of biology, Biology, Life sciences, Molecular biology, Laboratory techniques, Biotechnology, Nucleic acids, Molecular genetics, Oligonucleotide, Artificial gene synthesis, Polymerase chain reaction, Primer

By product, the synthesized oligonucleotides market is segmented into primers, probes, DNA oligos, RNA oligos, and other synthesized oligos such as BNA & LNA oligos.

Key Points: 
  • By product, the synthesized oligonucleotides market is segmented into primers, probes, DNA oligos, RNA oligos, and other synthesized oligos such as BNA & LNA oligos.
  • In 2020, the primers segment accounted for the fastest growing segment of this market, as they are used in various applications such as PCR, sequencing, gene synthesis, and cloning applications, among others.\nBased on application, the oligonucleotide synthesis market is segmented into therapeutic, research, and diagnostic applications.
  • The therapeutic application segment is further segmented into Antisense oligonucleotide-based therapies, siRNAi oligonucleotide-based therapies, and CpG oligonucleotide-based therapies.
  • Factors such as growing R&D funding, rising product availability, lower outsourcing costs, increasing research activities, increasing applications of oligos in molecular diagnostics & therapeutics, and the rising awareness of oligonucleotides are expected to drive market growth.\nNorth America accounted for the largest market share.

eureKARE launches with $60 million to build and finance next generation biotech companies in Europe

Retrieved on: 
Tuesday, May 18, 2021
Articles, Branches of biology, Biology, Molecular genetics, Appropriate technology, Biocybernetics, Biotechnology, Synthetic biology, Screening

It is forecast to reach $57 billion by 2028 at a CAGR of 25% per year.

Key Points: 
  • It is forecast to reach $57 billion by 2028 at a CAGR of 25% per year.
  • eureKARE aims to build bridges between these two bodies to create and support new ventures.
  • The Company supports translational research by creating and financing new companies out of high value European science through its biotech start-up studios eureKABIOME (Microbiome) and eureKASYNBIO (Synthetic biology).
  • Stellate is also evaluating a portfolio of new drug candidates in other conditions, with capabilities across discovery, screening, production and diagnostic development.\n'

eureKARE launches with $60 million to build and finance next generation biotech companies in Europe

Retrieved on: 
Tuesday, May 18, 2021
Articles, Branches of biology, Biology, Molecular genetics, Appropriate technology, Biocybernetics, Biotechnology, Synthetic biology, Screening

It is forecast to reach $57 billion by 2028 at a CAGR of 25% per year.

Key Points: 
  • It is forecast to reach $57 billion by 2028 at a CAGR of 25% per year.
  • eureKARE aims to build bridges between these two bodies to create and support new ventures.
  • The Company supports translational research by creating and financing new companies out of high value European science through its biotech start-up studios eureKABIOME (Microbiome) and eureKASYNBIO (Synthetic biology).
  • Stellate is also evaluating a portfolio of new drug candidates in other conditions, with capabilities across discovery, screening, production and diagnostic development.\n'